Combining a new targeted cancer drug with chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.

The new targeted therapy which could combat drug resistance has been found to be safe in early trials, allowing it to move to the next stage of development.

A new targeted treatment for ovarian cancer has shown ‘very promising’ results in an early clinical trial – shrinking tumours in half of women with the disease.